OPPM
PGNX

Opus Point Partners Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Opus Point Partners Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,891
Closed -$88K – 51
2018
Q2 		$88K Hold
10,891
– – 0.19% 48
2018
Q1 		$81K Sell
10,891
-10,891
-50% -$72.4K 0.16% 50
2017
Q4 		$130K Hold
21,782
– – 0.11% 64
2017
Q3 		$160K Hold
21,782
– – 0.14% 63
2017
Q2 		$148K Sell
21,782
-21,783
-50% -$161K 0.14% 66
2017
Q1 		$411K Buy
+43,565
New +$435K 0.31% 46

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Opus Point Partners Management's PGNX Position: Q3 2018 in Review

Opus Point Partners Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 10,891 shares — an estimated $88K sold.

Opus Point Partners Management first reported a position in PGNX in Q1 2017 and held it in 6 quarters. The position peaked at $411K in Q1 2017. 148 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Opus Point Partners Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Opus Point Partners Management sold 10,891 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $88K.
  • Opus Point Partners Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 6 quarters.
  • Opus Point Partners Management's Progenics Pharmaceuticals Inc position peaked at $411K in Q1 2017.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.